EMILY MILLER: Open Payments
NPI 1407239569 · CARMEL, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,083 in 61 payments from 15 companies in 2025. Trend: 2023 $732 · 2024 $923 · 2025 $1,083
Food & beverage: $1,083
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $397 |
| Novo Nordisk Inc | 11 | $174 |
| Neos Therapeutics, LP | 3 | $64 |
| Corcept Therapeutics | 3 | $60 |
| Axsome Therapeutics, Inc. | 2 | $56 |
| Amneal Pharmaceuticals LLC | 2 | $55 |
| Amgen Inc. | 3 | $46 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $41 |
| Astellas Pharma US Inc | 2 | $35 |
| Abbott Laboratories | 2 | $34 |
Products named: VRAYLAR, UBRELVY, Ozempic, Wegovy, Adzenys XR-ODT, Korlym, Auvelity, UNITHROID.
Industry payments across IN — which companies pay providers there.
